Hyperuricemia: Clinical Trials

10 trials for Hyperuricemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed. 10 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 310Completed 10
Phase 21Completed 1

Follow Hyperuricemia: new trials by email Literature Review of Hyperuricemia trials Research Report on Hyperuricemia

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
AR882 50 mg, AR882 75 mg, Placebo - Gout, Arthritis, Gouty
Phase 3CompletedArthrosi Therapeutics8662025-03-112026-09-28
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)
AR882 50 mg, AR882 75 mg, Placebo - Gout, Arthritis, Gouty
Phase 3CompletedArthrosi Therapeutics8182024-06-262026-10-14
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
Tigulixostat, Allopurinol, Placebo - Gout, Hyperuricemia
Phase 3CompletedLG Chem22022023-03-302025-07-22
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
Tigulixostat, Placebo - Gout, Hyperuricemia
Phase 3CompletedLG Chem3542022-10-252025-10-29
Prednisone for Heart Failure Patients With Hyperuricemia
Prednisone, Allopurinol - Heart Failure, Hyperuricemia
Phase 2 / Phase 3CompletedHebei Medical University2052013-12-012018-10-16
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
Febuxostat, Allopurinol - Cardiovascular Disease
Phase 3CompletedTakeda61982010-04-232018-06-14
Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia
TULY - Hyperuricemia
Phase 3CompletedVirchow Group1002010-02-012014-12-12
Efficacy and Safety of Oral Febuxostat in Participants With Gout
Febuxostat, Allopurinol - Gout
Phase 3CompletedTakeda22692007-02-012012-02-02
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
Rasburicase (SR29142), Allopurinol - Tumor Lysis Syndrome, Cancer
Phase 3CompletedSanofi2802004-04-012010-01-12
Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010
Febuxostat, Allopurinol - Gout
Phase 3CompletedTakeda10862003-07-012010-07-27

Narrower conditions

Gout (6)  ·  Arthritis, Gouty (2)  ·  Cardiovascular Diseases (1)  ·  Heart Failure (1)  ·  Leukemia (1)  ·  Lymphoma (1)  ·  Myelodysplastic Syndromes (1)  ·  Myocardial Infarction (1)  ·  Neoplasms (1)  ·  Stroke (1)  ·  Tumor Lysis Syndrome (1)

Broader conditions

Pathologic Processes (10)  ·  Pathological Conditions, Signs and Symptoms (10)  ·  Arthritis (6)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6)  ·  Crystal Arthropathies (6)  ·  Genetic Diseases, Inborn (6)  ·  Joint Diseases (6)  ·  Metabolic Diseases (6)  ·  Metabolism, Inborn Errors (6)  ·  Musculoskeletal Diseases (6)  ·  Nutritional and Metabolic Diseases (6)  ·  Purine-Pyrimidine Metabolism, Inborn Errors (6)  ·  Rheumatic Diseases (6)  ·  Heart Diseases (2)  ·  Bone Marrow Diseases (1)

Interventions

Allopurinol (6)  ·  Febuxostat (3)  ·  Prednisone (1)  ·  Urate Oxidase (1)  ·  rasburicase (1)

Sponsors

Takeda (3)  ·  Arthrosi Therapeutics (2)  ·  LG Chem (2)  ·  Hebei Medical University (1)  ·  Sanofi (1)  ·  Virchow Group (1)

Countries

United States (7)  ·  Australia (2)  ·  Georgia (2)  ·  New Zealand (2)  ·  Philippines (2)  ·  Taiwan (2)  ·  Thailand (2)  ·  Argentina (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Bulgaria (1)  ·  China (1)  ·  Colombia (1)  ·  Czechia (1)  ·  France (1)

Top investigators

Hyungjin Cho, MD (2)  ·  Robert Keenan, MD (2)  ·  Dr. Raghunadharao D (1)

Results publications

PMID 39929260, PMID 19286847, PMID 20370912, PMID 21353107, PMID 21849262, PMID 22052584, PMID 22132950, PMID 22316106, PMID 22436129, PMID 22795277, PMID 23683134, PMID 29527974, PMID 35536764